BMS to invest $650M in Japan: Asia News Roundup

（the article has been updated to make it concise and cohesive)

In a significant move, Bristol Myers Squibb (BMS) has announced plans to invest an additional ¥10 billion (around $650 million) in Japan. In an interview with Nikkei, the New Jersey-based U.S. drug maker highlighted that the investment would focus on developing four new drugs aimed at addressing the "Drug Loss" issue in Japan. The specific details regarding the drugs remain under wraps, but this investment signals BMS's commitment to expanding its footprint in Japan and contributing to resolving key challenges within the country’s healthcare system.

Meanwhile, in the field of regenerative medicine and cell therapy, Sumitomo Chemical has revealed plans to establish a new company, named Racthera, in collaboration with its subsidiary Sumitomo Pharma. Set to start operations in February 2025, Racthera will focus on research and business development in the regenerative and cell medicine space. The company plans to develop regenerative medical products, including those derived from iPS cells. By the mid-2030s, Sumitomo aims to generate sales of ¥100 billion, with expectations to reach up to ¥350 billion by 2040. Sumitomo Pharma will hold 66.6% of the new venture, with Sumitomo Chemical holding the remaining 33.4%.

On the regulatory front, Indoco Remedies, an Indian pharmaceutical manufacturer, received a warning letter from the U.S. FDA after an inspection at its Goa plant in July. While the company acknowledged the issues raised, it reiterated its commitment to addressing the concerns and ensuring compliance with U.S. regulations while continuing to supply products to the U.S. market.